Instrument Inactif

Communiqués LOCT WALK Nasdaq

Actions

LWACU

US54015L3015

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

EFFECTOR Therapeutics : Accelaration/Increase of Financial Obligation Form 8 K	26/06	PU
EFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq	24/06	AQ
EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	04/04	AQ
EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	05/02	AQ
EFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	25/01	AQ
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024	09/01	GL
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024	09/01	AQ
EFFECTOR Therapeutics Announces Reverse Stock Split	09/01	GL
EFFECTOR Therapeutics Announces Reverse Stock Split	09/01	AQ
EFFECTOR THERAPEUTICS ANNOUNCES NEW POSITIVE INTERIM DATA FROM DOSE ESCALATION AND PHASE 2 EXPANSION COHORTS OF ZOTATIFIN IN ER+ METASTATIC BREAST CANCER PATIENTS	11/12	AQ
EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients	08/12	GL
EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients	08/12	AQ
EFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer	28/11	GL
The role of STRIs in cancer	27/11	AQ
EFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting	15/11	GL
EFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	13/11	GL
EFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference	06/11	GL
EFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference	06/11	AQ
EFFECTOR THERAPEUTICS TO COLLABORATE WITH THE NORTHWESTERN UNIVERSITY DIVISION OF HEMATOLOGY AND ONCOLOGY ON AN INVESTIGATOR-INITIATED PHASE 1 DOSE ESCALATION TRIAL	25/10/23	AQ
EFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia	24/10/23	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués LOCT WALK Nasdaq

Actions

LWACU

US54015L3015

Communiqués

Filtres